ImageneBio (IMA) Q2 2024 earnings summary

Executive summary

• Focus shifted to clinical-stage targeted oncology, prioritizing IK-595 after discontinuing IK-930 and discovery efforts following two workforce reductions in 2024.

• Strategic review process initiated in May 2024 to explore potential transactions or alternatives; no definitive course of action approved yet.

• Full global rights to IK-175 and IK-412 regained after Bristol-Myers Squibb declined opt-in; no further collaboration revenue expected.

Financial highlights

• Net loss for Q2 2024 was $13.7 million, a 20% improvement year-over-year; six-month net loss was $29.9 million, down 5% from prior year.

• Research and development expenses fell 35% year-over-year for Q2 and 37% for the six months, reflecting program prioritization and headcount reductions.

• General and administrative expenses were flat for Q2 and up 7% for the six months, mainly due to Pionyr facility costs.

• Cash, cash equivalents, and marketable securities totaled $145.4 million as of June 30, 2024.

Outlook and guidance

• Cash runway expected to fund operations for at least 12 months from filing date.

• Ongoing costs anticipated for strategic review and continued IK-595 development; additional funding may be needed for future commercialization or expanded development.